Related Experiment Video
Updated: Nov 15, 2025
Implantation of Miniosmotic Pumps and Delivery of Tract Tracers to Study Brain Reorganization in Pathophysiological Conditions
Published on: January 18, 2016
Determining the Optimal Administration Conditions under Which MIF Exerts Neuroprotective Effects by Inducing BDNF
Chul Jung1, Mi Hee Kim2, Ye Yeong Kim2
1Asan Medical Center, Department of Rehabilitation Medicine, University of Ulsan College of Medicine, Seoul 05505, Korea.
Abstract:
Macrophage migration inhibitory factor (MIF) exerts neuroprotective effects against cerebral ischemia/reperfusion injury by inhibiting neuronal apoptosis and inducing the expression of brain-derived neurotrophic factor (BDNF). However, the optimal administration conditions of MIF are currently unknown. Here, we aimed to identify these conditions in an in vitro model. To determine the optimal concentration of MIF, human neuroblastoma cells were assigned to one of seven groups: control, oxygen and glucose deprivation/reperfusion (OGD/R), and OGD/R with different concentrations (1, 10, 30, 60, and 100 ng/mL) of MIF. Six groups were studied to investigate the optimal administration time: control, OGD/R, and OGD/R with MIF administered at different times (pre-OGD, OGD-treat, post-OGD, and whole-processing). Water-soluble tetrazolium salt-1 assay, Western blot analysis, and immunocytochemistry were used to analyze cell viability and protein expression. We found that 60 ng/mL was the optimal concentration of MIF. However, the effects of administration time were not significant; MIF elicited similar neuroprotective effects regardless of administration time. These findings correlated with the expression of BDNF and apoptosis-related proteins. This study provides detailed information on MIF administration, which offers a foundation for future in vivo studies and translation into novel therapeutic strategies for ischemic stroke.
Insights
Macrophage migration inhibitory factor (MIF) shows neuroprotection against ischemic stroke. The optimal concentration was 60 ng/mL, with administration timing not significantly affecting its beneficial effects.
Area of Science:
- Neuroscience
- Biochemistry
- Cell Biology
Background:
- Macrophage migration inhibitory factor (MIF) demonstrates neuroprotective properties against cerebral ischemia/reperfusion (I/R) injury.
- MIF mitigates neuronal apoptosis and upregulates brain-derived neurotrophic factor (BDNF) expression.
- Optimal administration conditions for MIF in neuroprotection remain undetermined.
Purpose of the Study:
- To ascertain the optimal concentration and administration timing of MIF for neuroprotection in an in vitro model of cerebral ischemia/reperfusion.
- To provide a foundation for future in vivo studies and therapeutic strategies for ischemic stroke.
Main Methods:
- Human neuroblastoma cells subjected to oxygen and glucose deprivation/reperfusion (OGD/R) model.
- Assessment of cell viability using water-soluble tetrazolium salt-1 assay.
- Analysis of protein expression (BDNF, apoptosis-related proteins) via Western blot and immunocytochemistry.
Main Results:
- The optimal concentration of MIF for neuroprotection was determined to be 60 ng/mL.
- MIF administration timing (pre-OGD, OGD-treat, post-OGD, whole-processing) did not significantly alter its neuroprotective effects.
- Observed neuroprotection correlated with modulation of BDNF and apoptosis-related protein expression.
Conclusions:
- A concentration of 60 ng/mL is identified as optimal for MIF-mediated neuroprotection in vitro.
- MIF exhibits consistent neuroprotective efficacy irrespective of administration timing in this model.
- Findings offer crucial insights into MIF administration for potential therapeutic applications in ischemic stroke.
